Increasing interests towards ‘edoxaban’ due to the NOAC benefit enlargement
Along with the news about the benefit enlargement, the industry has paid attention to the domestic acceptance period of the fourth New Oral Anti-Coagulant(NOAC).
According to the industry concerned on the 29th, Daiichi-Sankyo is expected to work on the approval procedure of the Ministry of Food ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
